Dr. Jennifer Litton is a board certified medical oncologist and professor of breast medical oncology at the University of Texas MD Anderson Cancer Center in Houston, where she is chief of the Section of Clinical Research and Drug Development for Breast Cancer. She also is a member of the Breast Immuno-Oncology Task Force of the National Cancer Institute. At the European Society for Medical Oncology 2019 Congress, she presented information on a study she's leading, looking at combining a new type of immunotherapy with a traditional chemotherapy medicine. She joined us to talk about current immunotherapy research for breast cancer in general as well as what is specifically being presented at the congress. Listen to the podcast to hear Dr. Litton discuss: why immunotherapy medicines to treat breast cancer will likely be used with another type of therapy, such as chemotherapy or radiation therapy the difference between a "hot" and "cold" tumor and why that is important for immunotherapy other biomarkers besides PD-L1 that may help doctors decided if an immunotherapy medicine will work

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related